Two new therapeutic strategies show promise in mouse models of hemophilia. One uses an RNA repair approach relying on trans-splicing to patch a genetic defect in a mouse model. Another aims at microparticles, cell fragments that seem to promote coagulation (pages 1015–1019 and 1020–1025).
References
High, K.A. Gene transfer as an approach to treating hemophilia. Circ. Res. 88, 137–144 (2001).
Kay, M.A. et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24, 257–261 (2000).
Manno, C.S. et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101, 2963–2972 (2003).
Roth, D.A., Tawa, N.E., O'Brien, J.M., Treco, D.A. & Selden, R.F. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N. Engl. J. Med. 344, 1735–1742 (2001).
Hrachovinova, I. et al. P-selectin/PSGL-1 interaction generates microparticles that correct hemostasis in a murine model of hemophilia A. Nat. Med. (2003).
Chao, H. et al. Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat. Med. (2003).
Falati, S. et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J. Exp. Med. 197, 1585–1598 (2003).
Myers, D. et al. New and effective treatment of experimentally induced venous thrombosis with anti-inflammatory rPSGL-Ig. Thromb. Haemost. 87, 374–382 (2002).
Bi, L. et al. Targeted disruption of the mouse factor VIII gene: a model for hemophilia A. Nat. Genet. 10, 119–121 (1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
High, K. Coaxing coagulation with RNA and cell fragments. Nat Med 9, 991–992 (2003). https://doi.org/10.1038/nm0803-991
Issue Date:
DOI: https://doi.org/10.1038/nm0803-991
- Springer Nature America, Inc.